Abstract
A key objective of the assessment working group of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was to identify, develop, evaluate, and validate outcome measures for use in clinical trials of psoriatic arthritis (PsA) and in clinical practice. In plenary and breakout sessions at the GRAPPA annual meeting (Boston, September 2007), the current status of measures used in clinical trials was reviewed, and development of simplified measures for use in various types of clinical practice (rheumatology, dermatology, and general practice) was discussed. We present a review of those discussions.
Key Indexing Terms:Footnotes
-
Supported by an unrestricted financial grant from Abbott, Centocor, Wyeth, Amgen, and UCB Pharma.
-
P.J. Mease, MD, Seattle Rheumatology Associates.
In this issue
